$ADMA News

ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings

Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript

ADMA Biologics (NASDAQ:ADMA) Shares Plunge on Q1 Miss and Revenue Guidance Cut

ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est

ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV

Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21

ADMA Biologics: The Short Report Is The Noise, Not The Signal

ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)

ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand

ADMA Biologics shares are trading higher after the company issued a response to short seller Culper Research to refute key allegations and alleviate confusion in the marketplace.

ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand

Why Are Shares Of ADMA Biologics Falling Today?

ADMA Biologics shares are trading lower after Cantor Fitzgerald downgraded its rating on the stock from Overweight to Neutral.

Cantor Fitzgerald Downgrades ADMA Biologics to Neutral

Short Seller Report Alleges ADMA Biologics Financial Misrepresentation

ADMA Responds To Short-Seller Report, Reviewing Assertions For Accuracy

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges